Biodesix (BDSX) Capital Expenditures (2019 - 2026)

Biodesix (BDSX) has 8 years of Capital Expenditures data on file, last reported at $81000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 640.0% year-over-year to $81000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $355000.0 (down 88.09% YoY) and the FY2025 annual result came in at $259000.0, down 91.98% from the prior year.
• Capital Expenditures eased to $81000.0 in Q1 2026, from $86000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $7.7 million in Q1 2023 to a low of -$20.0 million in Q4 2023.
• A 5-year average of $414176.5 and a median of $231000.0 in 2024 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 1747.21% in 2023, down 1034.83% in 2023.
• Tracing BDSX's Capital Expenditures over 5 years: stood at $2.1 million in 2022, then sank by 1034.83% to -$20.0 million in 2023, then soared by 104.2% to $839000.0 in 2024, then slumped by 89.75% to $86000.0 in 2025, then slipped by 5.81% to $81000.0 in 2026.
• The last three Capital Expenditures figures came in at $81000.0 (Q1 2026), $86000.0 (Q4 2025), and $48000.0 (Q3 2025), per Business Quant data.